Moonwalk Biosciences has raised $70 Million in New Series B Funding

According to filings with the U.S. Securities and Exchange Commission, Moonwalk Biosciences has raised $70,000,000.00 in new Series B funding. The federal securities law requires the notice to be...

Craig Etkin

October 7, 2026 2 Min Read

6 0

According to filings with the U.S. Securities and Exchange Commission, Moonwalk Biosciences has raised $70,000,000.00 in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Alpha Wave and YK Bioventures, Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures

About Moonwalk Biosciences
Moonwalk Biosciences is a biotechnology company developing first-in-class, adipose-targeted RNA therapies to treat obesity and cardiometabolic diseases by directly addressing the underlying biology of fat tissue. Leveraging a proprietary AI-enabled discovery platform, the company integrates deep human genetics, epigenomics, and multi-omics data with adipose-selective siRNA chemistry to identify and validate novel therapeutic targets in adipose biology without affecting appetite. Moonwalk is advancing a pipeline of adipose-targeted siRNA therapeutics designed to deliver durable weight loss, preserve lean mass, improve tolerability, and enable infrequent dosing, positioning the company as a differentiated player in the emerging field of precision RNA medicines for metabolic disease. The company operates from offices in South San Francisco and San Diego, reflecting its presence in major U.S. biotech hubs. Moonwalk emphasizes a data-driven, mechanistic approach to cardiometabolic disease that seeks to move beyond appetite suppression toward root-cause intervention in metabolic pathways.

To learn more, visit https://moonwalk.bio/
Linkedin: https://www.linkedin.com/company/moonwalk-biosciences/

Contact:
Alex Aravanis, Chief Executive Officer
https://www.linkedin.com/in/alex-aravanis-md-phd-3a9345